FindTrial
Sign In

INFLUENZA VIRUS INFECTIONS IN TRANSPLANT RECIPIENTS: A MULTICENTER REGISTRY

INFLUENZA VIRUS INFECTIONS IN TRANSPLANT RECIPIENTS: A MULTICENTER REGISTRY - AST Influenza

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35721
Enrollment
20
Registered
2011-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza infection virus infections

Interventions

None listed

Sponsors

University of Alberta
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Liver transplanta patients on at least one immunosuppressive medication

Exclusion criteria

Exclusion criteria: Unable to provide informed consent

Design outcomes

Primary

MeasureTime frame
The primary study endpoint is value of the Quantitative influenza PCR assay from NP swabs at the 6 measuring points as a measure for viral shedding after infection.—

Secondary

MeasureTime frame
Secondary endpoints include - immune response to Influenza at 4 and 6 weeks after infections - viral resistance testing at first and last positive swab - Subtyping of influenza virus—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)